

1  
2  
3  
4  
5  
6  
7  
8 **UNITED STATES DISTRICT COURT**  
9 **CENTRAL DISTRICT OF CALIFORNIA**  
10

11 ABDULADHIM A. ALGHAZWI,  
12 Individually and On Behalf of All Others  
13 Similarly Situated,

14 Plaintiff,

15 v.

16 THE BEAUTY HEALTH COMPANY,  
17 ANDREW STANLEICK, LIYUAN  
18 WOO, and MICHAEL MONAHAN,  
19 Defendants.

Case No. 2:23-cv-09733-SPG-MAA

**ORDER GRANTING THE  
DIJKGRAAFS' MOTION FOR  
APPOINTMENT AS LEAD  
PLAINTIFFS AND APPROVAL OF  
SELECTION OF LEAD COUNSEL  
AND DENYING THE BROWN AND  
JOU MOTIONS [ECF NOS. 14, 16, 19]**

20 Before the Court are the motions for the appointment of lead plaintiffs and  
21 corresponding approval of the selection of lead counsel filed by Priscilla and Martijn  
22 Dijkgraaf ("the Dijkgraafs"), (ECF No. 14 (the "Dijkgraaf Motion")); Jeff and Kevin  
23 Brown ("the Browns"), (ECF No. 16 (the "Brown Motion")); and Joseph Jou ("Jou"), (ECF  
24 No. 19 (the "Jou Motion")). The Dijkgraafs and Browns each filed oppositions to the  
25 competing motions, (ECF No. 24 ("Brown Opposition"); ECF No. 25 ("Dijkraaf  
26 Opposition")); Jou filed a notice of non-opposition to the competing motions, (ECF No. 23  
27 ("Jou Notice")). The Court has read and considered the matters raised with respect to the  
28 Motion and concluded that this matter is suitable for decision without oral argument. *See*

1 Fed. R. Civ. P. 78(b); C.D. Cal. L.R. 7-15. Having considered the parties' submissions,  
2 the relevant law, oral arguments, and the record in this case, the Court GRANTS the  
3 Dijkgraaf Motion and DENIES the Brown and Jou Motions.

4 **I. BACKGROUND**

5 Defendant The Beauty Health Company (the "Company") is a company focused on  
6 "skin health experiences"; its flagship brand, Hydrafacial, provides goods and services  
7 related to the dermatological procedure hyradermabrasion. (ECF No. 1 ("Compl.") ¶ 2).  
8 Hydrafacial's leading product is Syndeo, a machine that performs hyradermabrasion. (*Id.*).  
9 Hydrafacial launched Syndeo in the United States in March 2022. (*Id.*).

10 The Company's press releases and disclosures for the first three quarters of 2022  
11 expressed a rosy view of Syndeo's launch, touting a purportedly "strong rollout,"  
12 "exceptional results," "record Delivery Systems net sales," and a "strong demand for the  
13 Company's new Syndeo delivery system." (*Id.* ¶¶ 20–22). In February 2023, The  
14 Company issued a press release "reiterating its outlook" for growth in the 2023 fiscal year.  
15 (*Id.* ¶ 25). The Company subsequently, in March 2023, filed a Form 10-K with the  
16 Securities and Exchange Commission including language regarding the importance of  
17 customers' confidence in Defendants' products and the ingredients used therein. (*Id.* ¶ 26).  
18 In May 2023, the Company issued a press release "reconfirm[ing] [its] 2023 adjusted  
19 EBITDA margin guidance and long-term 2025 targets" and advertising, among other  
20 predictions, "continued strength in consumer demand" and "strong Syndeo traction  
21 globally." (*Id.* ¶ 27).

22 On August 9, 2023, however, the Company announced that its "second quarter 2023  
23 gross margin was 'unfavorably impacted' by a mix shift 'toward lower-margin refurbished  
24 devices'" and United States-based customers' choices to wait for further enhancements to  
25 Syndeo. (*Id.* ¶ 29). The Company also announced the "involuntary separation without  
26 cause" of its Chief Financial Officer ("CFO"), Liyuan Woo ("Woo"). (*Id.* ¶ 30). On  
27 November 13, 2023, the Company disclosed lower-than-expected United States revenue  
28

1 and the departure of its President, Chief Executive Officer, and Board member Andrew  
2 Stanleick (“Stanleick”). (*Id.* ¶ 5).

3 Plaintiff Abduladhim A. Alghazwi (“Alghazwi”) alleges that these disclosures were  
4 materially false or misleading. (*Id.* ¶ 7). Specifically, Alghazwi contends “that Syndeo 1.0  
5 and 2.0 devices had issues leading to ‘frequent treatment interruptions’”; that “the  
6 Company incurred significant costs to develop enhancements,” but that “providers  
7 continued to experience issues with the Syndeo devices” notwithstanding the  
8 enhancements; and “that, as a result, the Company would no longer market Syndeo 1.0  
9 and 2.0 devices,” causing it to “incur significant inventory writedowns.” (*Id.*). Alghazwi  
10 contends that these circumstances rendered positive statements about the Company’s  
11 prospects misleading and baseless. (*Id.*). Accordingly, on November 16, 2023, Alghazwi  
12 filed this class action suit on behalf of himself and a putative class against the Company,  
13 Woo, Stanleick, and the Company’s current CFO Michael Monahan (collectively,  
14 “Defendants”) in this Court. *See generally (id.)*.

15 On January 16, 2024, the Dijkgraafs, the Browns, and Jou each filed motions seeking  
16 appointment as lead plaintiff for the putative class and approval of their selection of lead  
17 counsel. (Dijkgraaf Mot.; Brown Mot.; Jou Mot.). On January 31, 2024, the Dijkgraafs  
18 and Browns each filed oppositions to the other putative class members’ competing motions,  
19 (Dijkgraaf Opposition; Brown Opposition), while Jou filed a notice of non-opposition to  
20 the same, (Jou Notice). The Dijkgraafs and Browns each filed replies in support of their  
21 respective motions on February 7, 2024. (ECF No. 26 (“Dijkgraaf Reply”); ECF No. 27  
22 (“Brown Reply”)).

## 23 **II. LEGAL STANDARD**

24 The Private Securities Litigation Reform Act (“PSLRA”) imposes early notice  
25 requirements on plaintiffs:

26 Not later than 20 days after the date on which the complaint is filed, the  
27 plaintiff or plaintiffs shall cause to be published, in a widely circulated  
28

1 national business-oriented publication or wire service, a notice advising  
2 members of the purported plaintiff class—

3 (I) of the pendency of the action, the claims asserted therein, and the  
4 purported class period; and

5 (II) that, not later than 60 days after the date on which the notice is  
6 published, any member of the purported class may move the court to  
7 serve as lead plaintiff of the purported class.

8 15 U.S.C. § 78u-4(a)(3)(A)(i).

9 After the plaintiff satisfies the notice requirement, a court “shall appoint as lead  
10 plaintiff the member or members of the purported plaintiff class that the court determines  
11 to be most capable of adequately representing the interests of class members.” 15 U.S.C.  
12 § 78u-4(a)(3)(B)(i). The PSLRA establishes a rebuttable presumption that “the most  
13 adequate plaintiff”:

14 (aa) has either filed the complaint or made a motion in response to a notice  
15 under subparagraph (A)(i);

16 (bb) in the determination of the court, has the largest financial interest in the  
17 relief sought by the class; and

18 (cc) otherwise satisfies the requirements of Rule 23 of the Federal Rules of  
19 Civil Procedure.

20 15 U.S.C. § 78u-4(a)(3)(B)(iii)(I). A competing putative class member may defeat this  
21 presumption with evidence “that the presumptively most adequate plaintiff” either “(aa)  
22 will not fairly and adequately protect the interests of the class; or (bb) is subject to unique  
23 defenses that render such plaintiff incapable of adequately representing the class.”  
24 15 U.S.C. § 78u-4(a)(3)(B)(iii)(II).

### 25 **III. DISCUSSION**

#### 26 **A. Alghazwi Satisfied the PSLRA’s Notice Requirement**

27 To comply with the PSLRA, a plaintiff must (1) publish notice within 20 days of  
28 filing their complaint in (2) “a widely circulated national business-oriented publication or

1 wire service,” advising the putative class of (3) “the pendency of the action, the claims  
2 asserted therein, and the purported class period,” as well as that (4), not later than 60 days  
3 after the notice’s publication, any member of the putative class may move to serve as lead  
4 plaintiff. 15 U.S.C. § 78u-4(a)(3)(A)(i).

5 Here, Alghazwi published notice of this lawsuit on November 16, 2023, the same  
6 day he filed suit. *Compare* (ECF No. 18-1 (Exhibit A to Declaration of Charles H. Linehan  
7 (“Linehan Ex. A”))) *with* (Compl.). Alghazwi published notice in *Business Wire*, (Linehan  
8 Ex. A), a national, widely-circulated, business-oriented wire service, (*see Ferreira v.*  
9 *Funko, Inc.*, No. 2:20-cv-02319-VAP-PJWx, 2020 WL 3246328, at \*4 (C.D. Cal. June 11,  
10 2020)). The notice stated that “Glancy Prongay & Murray LLP . . . has filed a class action  
11 lawsuit in the United States District Court for the Central District of California . . . on  
12 behalf of persons and entities that purchased or otherwise acquired The Beauty Health  
13 Company . . . securities between May 10, 2022 and November 13, 2023,” described the  
14 claims at issue, and notified investors “that they have 60 days from the date of this notice  
15 to move the Court to serve as lead plaintiff in this action.” (Linehan Ex. A at 2 (emphasis  
16 omitted)). Accordingly, Alghazwi’s notice in *Business Wire* satisfies the requirements of  
17 the PSLRA.

## 18 **B. Selection of Lead Plaintiffs**

19 Although three aspiring lead plaintiffs filed motions in response to Alghazwi’s  
20 notice, (Dijkgraaf Mot.; Brown Mot.; Jou Mot.), putative class member Joseph Jou (“Jou”)  
21 subsequently filed a Notice of Non-Opposition to Competing Motions for Appointment as  
22 Lead Plaintiff and Approval of Lead Counsel, recognizing that “Jou does not have the  
23 ‘largest financial interest’ in this litigation within the meaning of the PSLRA,” (Jou Notice  
24 at 2). The Court accordingly limits its analysis to the two parties who continue to compete  
25 to be appointed as lead plaintiffs: the Browns and the Dijkgraafs.

### 26 1. The Browns Are Presumptively the Most Adequate Lead Plaintiffs

27 Under the PSLRA, the presumptively most adequate plaintiff (1) “either filed the  
28 complaint or made a motion in response to a notice under subparagraph (A)(i)”; (2) “has

1 the largest financial interest in the relief sought by the class”; and (3) “otherwise satisfies  
2 the requirements of Rule 23 of the Federal Rules of Civil Procedure.” 15 U.S.C.  
3 § 78u-4(a)(3)(B)(iii)(I). As explained above, the Browns and the Dijkgraafs each moved  
4 to be appointed as lead counsel in response to Alghazwi’s notice. (Dijkgraaf Mot.; Brown  
5 Mot.). As a result, the Court must compare each party’s “financial interest in the  
6 litigation,” using accounting methods that are both “rational and consistently applied.” *In*  
7 *re Cavanaugh*, 306 F.3d 726, 730 n.4 (9th Cir. 2002).

8 Courts within the Ninth Circuit generally determine which party has the largest  
9 financial stake by reference to one of four metrics: “1) number of shares purchased during  
10 the class period; 2) net shares purchased during the class period; 3) net funds expended  
11 during the class period; and 4) approximate losses from the alleged fraud.” *In re McKesson*  
12 *HBOC, Inc. Sec. Litig.*, 97 F. Supp. 2d 993, 995 (N.D. Cal. 1999). *See also Ferreira*, 2020  
13 WL 3246328, at \*5 (same). A comparison of “the financial stakes of the various plaintiffs”  
14 reveals that the Browns have “the most to gain from the lawsuit.” *In re Cavanaugh*, 306  
15 F.3d at 730. By every metric—gross or net shares purchased, net funds expended during  
16 the class period, or approximate losses—the Browns’ financial stake vastly surpasses the  
17 Dijkgraafs’.<sup>1</sup> (Brown Opp. at 4).

18 Once a court “determines which plaintiff has the biggest stake, the court must  
19 appoint that plaintiff as lead, unless it finds that he does not satisfy the typicality or  
20 adequacy requirements.” *In re Cavanaugh*, 306 F.3d at 732. The court makes its initial  
21 Rule 23 determination as to that plaintiff, based on the information provided by the plaintiff  
22 in its pleadings. *Id.* at 730. “The test of typicality is whether other members have the same  
23 or similar injury, whether the action is based on conduct which is not unique to the named  
24

---

25 <sup>1</sup> Although the Court notes minor discrepancies with regard to Jeff Brown’s transactions  
26 between the source records filed by the Browns, (ECF No. 18-2), and the summary chart  
27 set forth in the Brown Opposition, these differences (amounting to approximately 3,000  
28 fewer net shares purchased) do not change the fact that the Browns purchased over 20 times  
more net shares and realized approximately losses approximately 4.5 times greater than the  
Dijkgraafs, *see* (Brown Opp. at 4).



1 plaintiffs, and whether other class members have been injured by the same course of  
2 conduct.” *Hanon v. Dataproducts Corp.*, 976 F.2d 497, 508 (9th Cir. 1992) (internal  
3 quotation marks and citation omitted). To determine whether a plaintiff meets Rule 23’s  
4 adequacy requirement, courts “ask two questions: (1) [d]o the representative plaintiffs and  
5 their counsel have any conflicts of interest with other class members, and (2) will the  
6 representative plaintiffs and their counsel prosecute the action vigorously on behalf of the  
7 class?” *Staton v. Boeing Co.*, 327 F.3d 938, 957 (9th Cir. 2003).

8 Here, the Browns allege that, “[l]ike all members of the class, the Browns suffered  
9 losses as a result of their Beauty Health transactions during the Class Period” arising from  
10 “the artificial inflation of Beauty Health’s share price caused by the Defendants’ alleged  
11 misrepresentations and omissions.” (ECF No. 17 at 8). As for adequacy, the Browns  
12 highlight the absence of any conflict between them and the class or their lawyers, and  
13 further emphasize their experience in investing. (*Id.* at 8–9). Based on these allegations,  
14 the Court preliminarily concludes that the Browns meet Rule 23’s typicality and adequacy  
15 requirements.

16 2. The Dijkgraafs Rebut the Presumption of Adequacy

17 After a presumptively most adequate lead plaintiff is identified, other plaintiffs have  
18 “an opportunity to rebut the presumptive lead plaintiff’s showing that it satisfies Rule 23’s  
19 typicality and adequacy requirements.” *In re Cavanaugh*, 306 F.3d at 730. Here, in  
20 opposition, the Dijkgraafs do not challenge the Browns’ adequacy as representatives under  
21 Rule 23—they do not contend that the Browns have conflicts of interest with the rest of the  
22 putative class or that they will otherwise be unable to vigorously prosecute this lawsuit.  
23 Instead, the Dijkgraafs contend that the Browns are not ‘typical’ as required by Rule 23  
24 because their trading activity subjects them to unique defenses. First, the Dijkgraafs  
25 contend that the Browns are atypical because they engaged in “unorthodox high frequency  
26 trading strategies.” (Dijkgraaf Opp. at 8). Specifically, the Browns conducted thousands  
27 of trades during the Class Period. (*Id.*). Additionally, on at least twenty occasions over  
28 the Class Period, Jeff Brown purchased substantial positions in the Company’s stock, then

1 sold those positions in their entirety. (*Id.*; ECF No. 25-2). Second, the Dijkgraafs challenge  
2 “large purchases” of Company shares that the Browns made “on November 13, 2023, after  
3 the market closed and immediately following the Company’s announcement of its third  
4 quarter 2023 financial results that revealed the [purported] fraud.” (Dijkgraaf Opp. at 9).  
5 The Dijkgraafs contend that these purchases undermine the Browns’ reliance on  
6 Defendants’ purported misrepresentations, subjecting them to “unique defenses.” (*Id.*  
7 at 10). The Court examines each issue in turn.

8       There is no *per se* bar against ‘in-and-out’ or day traders serving as putative class  
9 representatives in securities actions. *See, e.g., Welling v. Alexy*, 155 F.R.D. 654, 662 (N.D.  
10 Cal. 1994) (recognizing that “[d]istrict courts throughout the Ninth Circuit have . . .  
11 certified in/out traders as class members and representatives” and collecting cases); *In re*  
12 *Zynga Inc. Sec. Litig.*, No. C 12-04007 JSW, 2013 WL 257161, at \*2 (N.D. Cal. Jan. 23,  
13 2013) (concluding that a plaintiff’s status as a “day trader is inconsequential to his request  
14 to be appointed lead plaintiff”). Key to the analysis is whether the day trader can prove “a  
15 causal connection between the material misrepresentation and the loss” suffered. *Dura*  
16 *Pharms., Inc. v. Broudo*, 544 U.S. 336, 342 (2005). Where day traders sell their interest in  
17 a company prior to any curative disclosure, for example, they may not be unable to prove  
18 any economic loss based on those misrepresentations. *Id. See also In re Juniper Networks,*  
19 *Inc. Sec. Litig.*, 264 F.R.D. 584, 594 (N.D. Cal. 2009).

20       Here, the Complaint alleges one partial disclosure on August 9, 2023, prior to a full  
21 corrective disclosure on November 13, 2023. (Compl. ¶¶ 5, 29–30). In response to the  
22 Dijkgraafs’ arguments, the Browns emphasize that they maintained some number of shares  
23 in the Company “over both disclosures from May 25, 2023, through the end of the class  
24 period on November 13, 2023.” (Brown Reply at 5). Given the Browns’ ownership of  
25 shares throughout the relevant time periods, the Court declines to disqualify them on their  
26 day trading alone. Jeff Brown’s habit of fully closing out his position in Company stock,  
27 however, raises the risk that he may be subject to unique defenses with regards to his  
28 damages, undermining the typicality of his claims. Although it is possible Defendants



1 might not prevail on this argument, its determination would likely play a large role in this  
2 litigation and involve concomitant expense. *See In re Snap Inc. Sec. Litig.*, No. 2:17-cv-  
3 03679-SVW-AGR, 2019 WL 2223800, at \*2 (C.D. Cal. Apr. 1, 2019) (concluding that  
4 “potential problems regarding . . . typicality and adequacy” would likely “play a significant  
5 role at trial” and require prospective plaintiff “to devote class resources to defending  
6 itself”).

7 The Browns’ substantial purchases of Company stock following the Company’s  
8 November 13, 2023, disclosure are cause for additional concern. The Browns held 145,150  
9 shares through the November 13, 2023, disclosure, (Brown Reply at 3 n.2), before  
10 purchasing close to 200,000 additional shares directly following the disclosure, (ECF  
11 No. 18-2 at 47, 64, 76, 78–79). This substantial post-disclosure increase in the Browns’  
12 position could, as other courts have found in similar circumstances, undermine the Browns’  
13 ability to invoke the fraud-on-the-market presumption of reliance. *See, e.g., In re Snap*  
14 *Inc. Sec. Litig.*, 2019 WL 2223800, at \*2 (concluding plaintiff’s post-disclosure purchase  
15 of approximately 60% of total stock rendered him subject to unique defenses); *In re*  
16 *Valence Tech. Sec. Litig.*, No. C 95-20459 JW, 1996 WL 119468, at \*5 (N.D. Cal. Mar. 14,  
17 1996) (finding atypical plaintiff who tripled shares post-disclosure); *Faris v. Longtop Fin.*  
18 *Techs. Ltd.*, No. 11 CIV 3658 SAS, 2011 WL 4597553, at \*8 (S.D.N.Y. Oct. 4, 2011)  
19 (where plaintiff purchased 87% of stock post-disclosure, concluding there was “no reason  
20 to subject the class to this potential defense where” another movant had “purchased the  
21 vast majority of its . . . shares before the first corrective disclosure was made”).

22 In reply, the Browns note caselaw from within the Ninth Circuit holding that “that  
23 the purchase of stock after a partial disclosure is not a per-se bar to satisfying the typicality  
24 requirement.” *Hessefort v. Super Micro Computer, Inc.*, 317 F. Supp. 3d 1056, 1061 (N.D.  
25 Cal. 2018) (citation omitted). But the fact that such purchases do not always defeat  
26 typicality does not mean they never will. Indeed, courts in this district recognize that  
27 “unusual post-disclosure trading patterns present typicality problems.” *In re Countrywide*  
28 *Fin. Corp. Sec. Litig.*, 273 F.R.D. 586, 603 (C.D. Cal. 2009) (collecting cases) (emphasis

1 in original). Courts evaluate post-disclosure trading activity on a case-by-case basis; there  
2 is no bright-line rule delineating what activity is normal and what is expected. Here, based  
3 on the Browns' overall trading activity, the Court concludes that they are subject to unique  
4 defenses that undermine the typicality of their claims and DENIES their motion for  
5 appointment as lead plaintiff.

6 3. The Dijkgraafs Are Presumptively the Next Most Adequate Plaintiff

7 Where, as here, "the plaintiff with the greatest financial stake does not satisfy the  
8 Rule 23(a) criteria, the court must repeat the inquiry, this time considering the plaintiff  
9 with the next-largest financial stake." *In re Cavanaugh*, 306 F.3d at 730. With losses of  
10 at least \$78,390.84, (ECF No. 14-1 at 2), the Dijkgraafs are the moving party with the next  
11 largest financial interest in this lawsuit.<sup>2</sup> The Dijkgraafs meet their burden of establishing  
12 a preliminary showing of typicality and adequacy. *See Tanne v. Autobyte, Inc.*, 226 F.R.D.  
13 659, 667 (C.D. Cal. 2005) (holding that, in appointing a lead plaintiff, "a 'preliminary  
14 showing' is all that is necessary" with regards to satisfying typicality and adequacy).  
15 Regarding typicality, the Dijkgraafs argue that they "purchased [Company] securities  
16 during the designated class period and alleges losses as a result of those transactions" and  
17 assert that they "are not subject to any unique or special defenses." (ECF No. 14-1 at 5).  
18 The Dijkgraafs also deny having any conflicts of interest with other putative class  
19 members, and contend that their "very large financial loss" motivates them to vigorously  
20 prosecute this lawsuit. (*Id.* at 6).

21 4. No Party Rebutts the Presumption of the Dijkgraafs' Adequacy

22 Although the Browns oppose the Dijkgraaf Motion, they do so solely on the grounds  
23 that they, and not the Dijkgraafs, should be appointed lead plaintiffs. The Browns note that  
24 the Dijkgraafs also engaged in day trading, (Brown Reply at 4), but do not argue that this  
25 conduct disqualifies the Dijkgraafs from serving as lead plaintiffs. In any event, and as the  
26 Court has already held with regard to the Browns above, Section III.B.2, day trading alone

---

27  
28 <sup>2</sup> Jou alleges losses of approximately \$11,288. (ECF No. 20 at 5).

1 does not bar a plaintiff from serving as lead plaintiff. *See also Welling*, 155 F.R.D. at 662.  
2 “[O]nce the presumption is triggered, the question is not whether another movant might do  
3 a better job of protecting the interests of the class than the presumptive lead plaintiff;  
4 instead, the question is whether anyone can prove that the presumptive lead plaintiff will  
5 not do a fair and adequate job.” *Tanne*, 226 F.R.D. at 669 (quoting *In re Cendant Corp.*  
6 *Litigation*, 264 F.3d 201, 268 (3d Cir. 2001)). As no party has done so, and the Dijkgraafs  
7 satisfy their burden to show preliminary typicality and adequacy under Rule 23, the Court  
8 GRANTS their Motion to be appointed lead plaintiffs.

9 **C. Selection of Class Counsel**

10 The PSLRA provides that “[t]he most adequate plaintiff shall, subject to the approval  
11 of the court, select and retain counsel to represent the class.” 15 U.S.C.  
12 § 78u-4(a)(3)(B)(iii)(v). *See also In re Cavanaugh*, 306 F.3d at 733 n.11 (“At a later stage  
13 in the proceedings, the district court must approve the lead plaintiff’s choice of counsel,  
14 but Congress gave the lead plaintiff, and not the court, the power to select a lawyer for the  
15 class.”). The Ninth Circuit recognizes “a strong presumption in favor of approving a  
16 properly-selected lead plaintiff’s decisions as to counsel selection and counsel retention.”  
17 *Id.* at 734 n.14 (citation omitted). Indeed, “[a] court may disturb the lead plaintiff’s choice  
18 of counsel only if it appears necessary to ‘protect the interests of the class.’” *Tanne*, 226  
19 F.R.D. at 673 (quoting 15 U.S.C. § 78u-(a)(3)(B)(iii)(II)(aa)).

20 The Dijkgraafs request the Court approve their selection of the law firm Hagens  
21 Berman Sobol Shapiro LLP (“Hagens Berman”) as lead counsel. (Dijkgraaf Mot. at 2). In  
22 light of the Hagens Berman resume submitted in connection with the Dijkgraaf Motion,  
23 demonstrating the firm’s experience with and past successes in securities litigation, (ECF  
24 No. 14-7), and given the absence of any argument that the Dijkgraafs’ “choice of counsel  
25 is so irrational, or so tainted by self-dealing or conflict of interest, as to cast genuine and  
26 serious doubt on that plaintiff’s willingness or ability to perform the functions of lead  
27 plaintiff,” *In re Cavanaugh*, 306 F.3d at 733, the Court GRANTS the Dijkgraafs’ motion  
28 to approve their selection of Hagens Berman as lead counsel for the putative class.

1 **IV. CONCLUSION**

2 For the reasons stated herein, the Court GRANTS the Dijkgraaf Motion and  
3 DENIES the Brown Motion and Jou Motion. The Dijkgraafs are hereby appointed lead  
4 plaintiffs, and Hagens Berman is hereby appointed lead counsel.

5  
6 **IT IS SO ORDERED.**

7  
8 DATED: May 2, 2024



9  
10 HON. SHERILYN PEACE GARNETT  
11 UNITED STATES DISTRICT JUDGE  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28